1. Scrip
  2. >>Leadership

Drug Price Reform Concerns Novartis Pharma President Tschudin

Part 2 Of An Interview With Novartis's Marie-France Tschudin

 
• By Jessica Merrill

"We are definitely worried," Tschudin said about some US drug price reform proposals. She also spoke with Scrip about competitive rebating and new growth opportunities for anchor brands.

Novartis
Novartis Pharma President Tschudin talked with Scrip in an interview

The biopharma industry is facing increasing pressure from macro issues like the lasting impact from the pandemic and debate over drug pricing. In an interview with Scrip, Novartis AG's Pharmaceuticals president Marie-France Tschudin weighed in on US drug price reform, competitive rebating and how COVID-19 has changed the way the industry operates, as well as on some of the long-term growth opportunities for the company's anchor brands.

The first part of the interview, held in New York City on 16 September, focused on the ongoing COVID-19 recovery and new launches at Novartis, including Kesimpta (ofatumumab) in multiple sclerosis and Leqvio (inclisiran) for high cholesterol, which could soon be approved in the US

More from Leadership

More from Scrip

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.